$SABS News
Last published 3d ago
- 3d agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences:
- 3d agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 1w agoSABSSAB BIO Q3 2026 Earnings Call - SAB BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to SABbio's conference call to discuss third quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from this mornin
- 1w agoSABSSAB BIO Q3 2026 Earnings Call - SAB BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to SABbio's conference call to discuss third quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from this mornin
- 1w agoSABSSABSWSAB BIO Reports Q3 2026 Financial Results and Provides Business HighlightsGlobeNewswireAdult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast
- 2w agoSABSSABSWSAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ETGlobeNewswireMIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 3w agoSABSChardan Healthcare Conference – 10 Years of Disruptive Innovation - SAB BIOTHERAPEUTICS INCEarnings Call TranscriptsGreat. Okay. Well, let's go ahead and get started with this session, Developing Biological Systems as Therapeutics. My name is Kane Akai. I'm the Director of Research and one of the Senior Biotech Analysts at Chardon. Jo
- 4w agoSABSSABSWSAB BIO to Participate in Chardan 10th Annual Healthcare ConferenceGlobeNewswireMIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 1mo agoSABSSABSWSAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 DiabetesGlobeNewswireFast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes MIAMI, Oct. 13, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a
- 2mo agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 3mo agoSABSSAB Bio's Q2 2026 Earnings Call - SAB BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning and welcome to SAB Bios, conference call to discuss second quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from this morni
- 3mo agoSABSSAB Bio's Q2 2026 Earnings Call - SAB BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning and welcome to SAB Bios, conference call to discuss second quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from this morni
- 3mo agoSABSSABSWSAB BIO Reports Q2 2026 Financial Results and Provides Business HighlightsGlobeNewswireOver 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027
- 3mo agoSABSSABSWSAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ETGlobeNewswireMIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 4mo agoSABSSABSWBreakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 DiabetesGlobeNewswireMIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical
- 5mo agoSABSSABSWSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual MeetingGlobeNewswireMIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 6mo agoSABSSABSWSAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsGlobeNewswireContinued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142
- 6mo agoSABSSABSWSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETGlobeNewswireMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 6mo agoEBSSABSEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142GlobeNewswireGAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (NASDAQ:SABS, SAB BIO)) to support the process
- 6mo agoSABSSABSWSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026GlobeNewswireAll 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved
- 7mo agoSABSSABSWSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressGlobeNewswireMIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 8mo agoSABSSABSWSAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 DiabetesGlobeNewswireResults demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB
- 8mo agoSABSSABSWSAB BIO Reports Full Year 2025 Financial Results and Business HighlightsGlobeNewswireAdvanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1
- 8mo agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 9mo agoSABSGUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026 - SAB BIOTHERAPEUTICS INCEarnings Call TranscriptsAll right. Thank you. Good morning, everyone. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. It is my pleasure to welcome you all to our Emerging Outlook Biotech Summit 2026. Our next presenting
- 9mo agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and
- 10mo agoSABSSABSWSAB BIO Strengthens Board of Directors with Appointment of New Chair and New DirectorGlobeNewswireDavid Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage
- 10mo agoSABSSABSWFirst Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1DGlobeNewswireEnrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a
- 11mo agoSABSSABSWSAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1DGlobeNewswirePhase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing of SAB-142 in an
- 11mo agoSABSSABSWSAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes ManagementGlobeNewswireMIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other
- 12mo agoSABSSABSWSAB BIO Reports Third Quarter Financial Results and Recent Business HighlightsGlobeNewswireInitiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent data presented at EASD
- 1y agoSABSSABSWSAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142GlobeNewswireMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other
- 1y agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune diseases, including its
- 1y agoSABSSABSWSAB BIO Highlights Data in Multiple Presentations at EASDGlobeNewswire-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in
- 1y agoSABSSABSWSAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of DiabetesGlobeNewswireMIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a
- 1y agoSABSSABSWSAB BIO Reports Second Quarter Financial Results and Highlights Company UpdatesGlobeNewswireRecently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until
- 1y agoSABSSABSWSAB BIO Announces Oversubscribed $175 Million Private PlacementGlobeNewswireParticipation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and
- 1y agoSABSSABSWSAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesGlobeNewswireMIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte
- 1y agoSABSSABSWSAB BIO Reports Full Year 2024 Operating and Financial ResultsGlobeNewswireMIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte
- 1y agoSABSSABSWSAB BIO to Participate in Upcoming Investor ConferencesGlobeNewswireMIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human
- 1y agoSABSSABSWSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142GlobeNewswireSAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is
- 2y agoSABSSABSWSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateGlobeNewswireCompany announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024
- 2y agoSABSSABSWSAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewswireMIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin
- 2y agoSABSSABSWSAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare ConferenceGlobeNewswireMIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin
- 2y agoSABSSABSWSAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual MeetingGlobeNewswireSAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study. Target dose of SAB-142 2.5mg/kg completed
- 2y agoSABSSABSWSAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingGlobeNewswireMIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin
- 2y agoSABSSABSWSAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesGlobeNewswireFDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the
- 2y agoSABSSABSWSAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesGlobeNewswireMIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human
- 2y agoSABSSABSWSAB BIO Appoints Lucy To as Chief Financial OfficerGlobeNewswireMIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human
- 2y agoSABSSABSWSAb Biotherapeutics Rebrands as SAB BIOGlobeNewswireNew name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB